By Arezou Azarani | January 27, 2020 at 03:12 PM EST | No Comments
Dr. Ayati talked about how to help people with dementia at the Avenidas' 16th Annual Caregiver Conference: "Rather than endless medical tests and drugs, what is really needed is more training in geriatric care for doctors and nurses, Ayati said. In the U.S., the current norm is spending less on social services and more on health care – after people become ill. One in nine people age 65 and over has dementia, he said, with many more undiagnosed. Cutting back on unnecessary and ineffective drugs, medical treatments and procedures, and using that money to pay family caregivers in order to keep seniors home, where they want to be, is the way to go."
What they have discovered is that in the presence of antibiotics, the bacteria are able to change from a highly regular walled form to a completely random, cell wall-deficient form called the L-form state. As such, the bacteria can easily hide from our immune system as well as antibiotics.
In L-form the bacteria are weaker but some survive, hiding inside the body. They can then re-form their cell wall and the patient will be faced with recurring UTIs.
By Arezou Azarani | January 16, 2020 at 05:06 PM EST | No Comments
Every 3 seconds in the world someone develops dementia. Dementia is caused by damage to brain cells. Therefore, brain cells can no longer communicate with each other and the brain cannot carry out its regular functions. While the exact cause of it is unknown it could be caused by genes (and be inherited) , vascular issues (for example, stroke), brain injury (concussion), disease, or environmental factors.
By Arezou Azarani | September 12, 2019 at 03:13 PM EDT | No Comments
Dr. Ayati will speak about "The Challenges of Caregiving and Aging in America!”Dr. Ayati will highlight his testimony before the U.S Senate Special Committee on Aging concerning the essential role of the family caregiver: public efforts to enhance healthy aging, access to resources and Medicare coverage for custodial care. Sept, 28th, 2019, at 8:00 AM. Address: Mountain View Senior Center 266 Escuela Avenue Mountain View, CA 94040
Welcome Address: Supervisor Wasserman Keynote Speaker: Dr. Mehrdad Ayati Date: Aug 27, 2019 Location: Leininger Community Center - Okayama Room, 1300 Senter Rd., San Jose, CA 95112
By Arezou Azarani | July 11, 2019 at 01:16 PM EDT | No Comments
Scientists reported that exposure to anticholinergic drugs such as antidepressants (for example, paroxetine or amitriptyline), bladder antimuscarinics (for example, oxybutynin or tolterodine), antipsychotics (for example, chlorpromazine or olanzapine) and antiepileptic drugs (for example, oxcarbazepine or carbamazepine) increase the risk of dementia by about 50%.Read the full report here.
By Arezou Azarani | April 01, 2019 at 12:48 PM EDT | No Comments
Dr. Ayati spoke at the Elder Summit, Improving care through knowledge, partnership & empowerment at El Camino Hospital on May 17th, 2019 from 8:30 AM to 2:30 PM
By Arezou Azarani | March 06, 2019 at 08:27 PM EST | No Comments
Alzheimer's Association is reporting that Primary Care physicians are not performing cognitive assessment on seniors. "Despite a strong belief among seniors and physicians that cognitive assessments are important for the early detection of Alzheimer's, only half of the seniors in the survey were being assessed for cognitive decline. And only 16% [of] seniors received regular followup assessments."
By Arezou Azarani | December 13, 2018 at 03:43 PM EST | No Comments
Dr. Mehrdad Ayati will discuss managing chronic conditions in aging with the goal of maintaining a better quality of life at Rosener House. 500 Arbor Road, Menlo Park, on Wednesday, Jan 16, 2019 at 6:30. Dr. Ayati’sgoal is to provide reliable information, effective strategies and guidelines to navigate challenges such as mild cognitive impairment, Alzheimer’s, dementia, post-stroke, and Parkinson’s disease. Dr. Ayati is an advocate of his patient’s physical and mental health at any age in addition to disease management and prevention. Admission is FREE.
By Arezou Azarani | December 10, 2018 at 04:27 PM EST | No Comments
"The US Food and Drug Administration says another heart medicine is being voluntarily recalled after tests showed that it was tainted with a potential cancer-causing chemical."
"The new recall of losartan potassium hydrochlorothiazide is sold by the company Sandoz. The voluntary recall only involves the 100 milligram/25 milligram tablets, it does not involve the other versions of the drug, sometimes sold under the brand names Hyzaar. If you take Sandoz's losartan potassium, look on the bottle for the lot number. If it has the lot number JB8912, then you have the recalled pills. Patients use these drugs to keep their high blood pressure in check."
"With some drugs, like statins or arthritis drugs, the effects of poor quality are confined to those taking them. With antimicrobials, inappropriate use reduces their effectiveness for everyone else...."
By Arezou Azarani | January 22, 2018 at 06:54 PM EST | No Comments
Dr Ayati is invited by Senator Susan Collins, chair of the Senate Special Committee on Aging, to speak about Aging and Challenges Faced by the Aging Population in the US, on Wed Jan 24th, 2018 at 9:30 AM ET. The discussion will be broadcasted live on the committee’s website : www.aging.senate.gov
By Arezou Azarani | December 14, 2017 at 04:20 PM EST | No Comments
A temperature controlled truck was transporting expensive human Albumin and human Immunoglobin pharmaceuticals when it got into an accident. Human Albumin has numerous clinical uses. For instance, it is used in the emergency treatment of shock, where the restoration of blood volume is urgent. It is also used to prevent hemoconcentration (increased concentration of cellular elements in the blood resulting from loss of fluid to the tissues) and to maintain appropriate electrolyte balance in burned patients. Furthermore, it is used to treat hypoproteinemia (low concentration of plasma protein and a resulting decreased circulating blood volume) due to protein malnutrition, protein catabolism (breakdown of proteins into amino acids) postoperatively or in sepsis, defective gastrointestinal absorption, faulty albumin synthesis in chronic hepatic failure, and abnormal renal losses due to chronic kidney dieses. Human Albumin is purified from large pools of adult human venous plasma via a highly complex and expensive process. The human albumin solution is sterilized for usage in the aforementioned clinical purposes.
Human immunoglobulins are proteins (also called antibodies) produced by B-lymphocytes to help prevent and treat bacterial, fungal and viral infections. Human immunoglobulin solution is used as replacement therapy for primary humoral immunodeficiency (disorders that affect the cells, tissues, and proteins of the immune system) in cases such as the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Human immunoglobulin is manufactured from human source or recovered plasma and sterilized for clinical purposes.
Human Albumin and human Immunoglobin are packaged in glass bottles/vials and stored between 20-25ºC (68-77ºF) with short excursions permitted between 15-30ºC (59-86ºF). They should not be subject to drastic temperature changes or subfreezing temperatures, which might compromise their functionality. The vials should not be shaken vigorously and should be kept in their original carton to protect them from light.
When the trailer transporting 32 pallets of these plasma pharmaceuticals got involved in a collision it was heavily damaged and the refrigeration unit became inoperable. At the time of the accident, the outside temperature was well below 0ºC. As such the products were subject to both physical damage and long term temperature abuse. The plaintiff (pharmaceutical company) claimed that these products were rendered useless for pharmaceutical purposes and disposed all of the vials. The pharmaceutical company set the value of the products at $3.4 million and filed a claim against the freight company for this amount.
I was hired by the defendant (the law firm hired by the carrier’s insurance company) to first analyze all the data/facts and determine whether the pharmaceutical company’s claim of unusability of the product for clinical purpose was valid and also to determine whether the products could have been salvaged for other applications purposes rather than being destroyed by the pharmaceutical company.
After thorough examination of all the reports I determined that the products indeed could not have been used for clinical purposes. Most of the glass bottles/vials used for the storage of the products had visible cracks. These cracks exposed the solution to air and rendered the solution unsterile with a high chance of bacterial and viral contamination. Since these pharmaceutical products are used in human subject they can only be used sterile to prevent infections. Furthermore, drastic temperature variations, exposure to subfreezing temperature, light exposure (due to the breakage of the outer packaging), and vigorous shaking of the vials during the accident subjected the products to potential denaturation (a process by which the proteins became inactive) and product degradation.
However, while the products in question could no longer have been used for clinical purposes the pharmaceutical company should not have discarded the products since they could have been used in nonclinical applications. I provided a thorough list of molecular biology procedures by which the products in question could have been tested in order to determine their concentration, activity and possible contamination levels. I also provided a long list of life sciences research applications and cosmetic applications they could have been utilized in. Furthermore, I provided a molecular biology research price structure for the products in question and compared that to the clinical value of these products. For example, human Immunoglobin could have been sold for molecular biology research applications for a price seven times higher than if it was sold for clinical purposes. In conclusion, if the pharmaceutical company had not disposed the products in question they could have been analyzed by molecular biology assays to determine their activity level and sold into life sciences and cosmetic industry at a much higher price point. As a result of my contributions to this case the law firm was able to settle the case with the pharmaceutical company and reduce the claim by more than 1.5 million dollars (or by over 50%).
"HOW SAFE ARE YOUR ELDERLY LOVED ONES? There’s no way to know about abuse that goes unreported. But you can look up the name of a nursing home in federal inspection data and see whether it has been cited for sexual abuse or other issues in the past three years. Here's how:
On the first page of results, you will see a star rating for the facility based on factors such as staffing levels. A history of abuse or other inspection problems will typically be reflected in the "health inspection" rating.
Click on the health inspection rating to see a summary of the facility's most recent inspection.
From here, click on "View all health inspections." For details, go to a specific date and click "View full report."
From the main profile page for the facility, click on "Penalties" to see if an inspection resulted in fines or payment denials.
To view older citations, download archived reports here or file a public records request here. Some states may also offer detailed information. A list of state websites is here." From CNN
By Arezou Azarani | December 06, 2016 at 06:55 PM EST | No Comments
Researchers have found that the presence of certain type of bacteria in human intestines can result in the development of Parkinson's disease. It is beleived that these bacteria are releasing chemicals that over-activate parts of the brain, leading to neurodegenerative damage. Scientists hope to develop drugs or probiotics that work in the digestive system in order to cure/prevent the disease.
By Arezou Azarani | November 29, 2016 at 06:33 PM EST | No Comments
The world's largest dementia research experiment conducted by scientists at University College London, which takes the form of a video game called Sea Hero Quest, has indicated the ability to navigate declines throughout life. Players aged 19 were 74% accurate at playing the game, but accuracy fell year by year until it reached 46% at age 75. Read more....
I was highly disappointed and saddened to find this new negative venture from LinkedIn! While I have the greatest respect for leaders included in this list I find it very upsetting that there is age discrimination involved. I am a very strong advocate of equality. Why should there be an age component attached to leadership? What message are we sending to our society? That only people under the age of 35 can innovate and lead successful companies? When LinkedIn started, we all joined in to find connections, jobs, share our expertise and knowledge, form networks, and use it as a platform to share our voice with regard to issues that matter most in our fields and society. I never thought it would lead to our information being used to discriminate about our age!
Yesterday, I had a conversation with one of my great colleagues. When it comes to the biotechnology/pharmaceutical industry he is as accomplished and savvy as it gets. I have the outmost respect and appreciation for his expertise and many years of top notch experience in my filed. He was telling me that he, as I have heard from many other colleagues, is deeply disappointed in the way the employee selection in our industry is progressing for the past decade. He said that there is a lot of resistance toward hiring older employees at work. If you go through an extensive interview process and have all the qualifications necessary for a position, over 90 percent of the times you can be sure that a younger candidate gets selected over the older one. Why we discussed? Many theories came to our mind and we discussed the topic extensively. Whatever the underlying reason, I strongly believed that discriminations, including age discrimination is a very negative trend and something I strongly oppose. In my opinion, this new project from LinkedIn is sending the wrong message to our society. I am a very strong believer that innovation, professionalism, top expertise and great leadership are qualities that have nothing to do with age and everything to do with hard work, dedication, and selflessness. Furthermore, I believe that our great accomplishments and achievements in life are somewhat personal in nature and not a subject to brag about. Are we (or in this case LinkedIn) trying to prove something to ourselves or to our colleagues?
I do not wish to receive this list any longer from LinkedIn and strongly recommend that LinkedIn discontinues this controversial project. If you agree with me please write to LinkedIn and oppose this movement.
Hope (Arezou) Azarani
Our services and solutions enhance your productivity, performance, precision and throughput
